化疗联合DIK细胞治疗在食管癌的临床应用  

Application of DIK combined with chemotherapy in the treatment of advanced esophagus cancer

作　　者：顾敏威[1] 孙振宇[1] 王敏锋[1] 

机构地区：[1]无锡市第三人民医院心胸外科,江苏无锡214041

出　　处：《湖南中医药大学学报》2013年第12期15-15,18,共2页Journal of Hunan University of Chinese Medicine

摘　　要：目的研究以DIK细胞治疗联合化疗治疗食管癌的临床应用价值。方法回顾分析本院以DIK联合化疗治疗的15例食管癌患者的病历资料,与同期仅化疗治疗的15例患者进行对照研究。分析两种治疗的总有效率和患者治疗前后免疫学指标。结果联合组OR 73%,CBR 87%;化疗组OR 53%,CBR 73%,联合组临床有效率明显高于化疗组,差异有统计学意义(P<0.05);联合组治疗后外周血CD3+、CD4+、CD4+/C D8+及NK细胞比率较治疗前明显升高,且高于化疗组,以上差异均有统计学意义(P<0.05);DIK治疗后患者血清IL-2、IL-12、IFN-γ、TNF-α水平均较治疗前显著上升,差异有统计学意义(P<0.05)。结论DIK联合化疗能提高食管癌患者化疗后的免疫学功能指标,提高化疗疗效,提高患者生存质量。Objective To study the DIK combined with chemotherapy in the treatment of esophagus cancer. Methods A retrospective analysis of clinical data of 15 cases of esophagus cancer patients with DIK combined chemotherapy treatment, compared with 15 patients only treated with chemotherapy. We also analyse two kinds of immunological indexes and the total efficiency before and after treatment. Results The combined group OR was 73%, CBR 87%;chemotherapy group OR 53%, CBR 73% （P^0.05）.The combined group after treatment, peripheral blood CD3＋, CD4＋, CD4＋/CD8＋ and NK cell ratio significantly increased （P^O,05）, which is higher than the chemotherapy group （P〈0.05）. After DIK treatment, serum IL-2, IL-12, 1FN- γ, TNF- α levels were significantly increased compared with those before treatment （P〈0.05）. Conclusion DIK combined with chemotherapy can improve the index of immunological function of patients with esophagus cancer after chemotherapy, enhancing the curative effect of chemotherapy, and improve patients＇ quality of life.

关 键 词：生物治疗 DIK细胞治疗 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]